{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T06:47:55Z","timestamp":1775544475318,"version":"3.50.1"},"reference-count":42,"publisher":"BMJ","issue":"7","license":[{"start":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T00:00:00Z","timestamp":1604275200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"crossref","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Arch Dis Child"],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Early diagnosis and treatment initiation are important factors for successful treatment of mucopolysaccharidosis type I (MPS I). The purpose of this observational study was to assess whether age at diagnosis and time to first treatment for individuals with MPS I have improved over the last 15 years.<\/jats:p><\/jats:sec><jats:sec><jats:title>Study design<\/jats:title><jats:p>Data from the MPS I Registry (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT00144794\">NCT00144794<\/jats:ext-link>) for individuals with attenuated or severe disease who initiated therapy with laronidase enzyme replacement therapy (ERT) and\/or hematopoietic stem cell transplantation (HSCT) between 1 January 2003 and 31 December 2017 were included.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Data were available for 740 individuals with attenuated (n=291) or severe (n=424) MPS I (unknown n=25). Median age at diagnosis for attenuated disease did not change over time and ranged between 4.5 and 6 years of age while the median duration from diagnosis to first ERT decreased from 5.6 years before\/during 2004 to 2.4 months in 2014\u20132017. For severe MPS I treated with HSCT, median age at diagnosis was less than 1 year and median time to first treatment was less than 3 months throughout the 15-year observation period.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Times to diagnosis and HSCT initiation for individuals with severe MPS I were consistent over time. For individuals with attenuated MPS I, the time to ERT initiation after diagnosis has improved substantially in the last 15 years, but median age at diagnosis has not improved. Efforts to improve early diagnosis in attenuated MPS I are needed to ensure that patients receive appropriate treatment at the optimal time.<\/jats:p><\/jats:sec>","DOI":"10.1136\/archdischild-2020-319040","type":"journal-article","created":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T22:25:35Z","timestamp":1604355935000},"page":"674-679","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":19,"title":["Improvement in time to treatment, but not time to diagnosis, in patients with mucopolysaccharidosis type I"],"prefix":"10.1136","volume":"106","clinical-trial-number":[{"clinical-trial-number":"nct00144794","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00144794","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9655-3686","authenticated-orcid":false,"given":"Roberto","family":"Giugliani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Muschol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hillary A.","family":"Keenan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Dant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Muenzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2020,11,2]]},"reference":[{"key":"2022100607501402000_106.7.674.1","doi-asserted-by":"crossref","first-page":"v4","DOI":"10.1093\/rheumatology\/ker394","article-title":"Overview of the mucopolysaccharidoses","volume":"50 Suppl 5","author":"Muenzer","year":"2011","journal-title":"Rheumatology"},{"key":"2022100607501402000_106.7.674.2","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-3-24"},{"key":"2022100607501402000_106.7.674.3","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/ajmg.a.61456","article-title":"Estimated birth prevalence of mucopolysaccharidoses in Brazil","volume":"182","author":"Federhen","year":"2020","journal-title":"Am J Med Genet A"},{"key":"2022100607501402000_106.7.674.4","unstructured":"Neufeld E , Muenzer J . The mucopolysaccharidoses. In: Schriver C , Beaudet A , Sly W , et al , eds. The metabolic and molecular basis of inherited disease. New York: McGraw Hill, 2001: p. 3421\u201352."},{"key":"2022100607501402000_106.7.674.5","doi-asserted-by":"publisher","DOI":"10.1007\/s10545-010-9113-7"},{"key":"2022100607501402000_106.7.674.6","first-page":"743","article-title":"Alpha-L-Iduronidase therapy for mucopolysaccharidosis type I","volume":"2","author":"Tolar","year":"2008","journal-title":"Biologics"},{"key":"2022100607501402000_106.7.674.7","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2008-0416"},{"key":"2022100607501402000_106.7.674.8","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-6-55"},{"key":"2022100607501402000_106.7.674.9","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.6.3.489"},{"key":"2022100607501402000_106.7.674.10","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.ymgme.2016.01.011","article-title":"Enzyme replacement therapy prior to haematopoietic stem cell transplantation in Mucopolysaccharidosis Type I: 10 year combined experience of 2 centres","volume":"117","author":"Ghosh","year":"2016","journal-title":"Mol Genet Metab"},{"key":"2022100607501402000_106.7.674.11","doi-asserted-by":"publisher","DOI":"10.1590\/S1415-47572012000600006"},{"key":"2022100607501402000_106.7.674.12","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.ymgme.2013.04.023","article-title":"Does early use of enzyme replacement therapy alter the natural history of mucopolysaccharidosis I? Experience in three siblings","volume":"109","author":"Laraway","year":"2013","journal-title":"Mol Genet Metab"},{"key":"2022100607501402000_106.7.674.13","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ymgme.2013.11.015","article-title":"Early initiation of enzyme replacement therapy for the mucopolysaccharidoses","volume":"111","author":"Muenzer","year":"2014","journal-title":"Mol Genet Metab"},{"key":"2022100607501402000_106.7.674.14","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1002\/ana.24246","article-title":"Early treatment is associated with improved cognition in Hurler syndrome","volume":"76","author":"Poe","year":"2014","journal-title":"Ann Neurol"},{"key":"2022100607501402000_106.7.674.15","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2009-1728"},{"key":"2022100607501402000_106.7.674.16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-11-608075"},{"key":"2022100607501402000_106.7.674.17","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-011-1644-x"},{"key":"2022100607501402000_106.7.674.18","doi-asserted-by":"publisher","DOI":"10.1080\/08035250510031584"},{"key":"2022100607501402000_106.7.674.19","doi-asserted-by":"publisher","DOI":"10.1038\/gim.2014.25"},{"key":"2022100607501402000_106.7.674.20","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ymgmr.2016.07.006","article-title":"The diagnostic journey of patients with mucopolysaccharidosis I: a real-world survey of patient and physician experiences","volume":"8","author":"Bruni","year":"2016","journal-title":"Mol Genet Metab Rep"},{"key":"2022100607501402000_106.7.674.21","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.ymgme.2012.08.008","article-title":"Experiences of parents and patients with the timing of Mucopolysaccharidosis type I (MPS I) diagnoses and its relevance to the ethical debate on newborn screening","volume":"107","author":"de Ru","year":"2012","journal-title":"Mol Genet Metab"},{"key":"2022100607501402000_106.7.674.22","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-017-0733-y","article-title":"Failure to shorten the diagnostic delay in two ultra-orphan diseases (mucopolysaccharidosis types I and III): potential causes and implications","volume":"13","author":"Kuiper","year":"2018","journal-title":"Orphanet J Rare Dis"},{"key":"2022100607501402000_106.7.674.23","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.32320"},{"key":"2022100607501402000_106.7.674.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2007.01.011"},{"key":"2022100607501402000_106.7.674.25","doi-asserted-by":"publisher","DOI":"10.1111\/j.1651-2227.1995.tb13640.x"},{"key":"2022100607501402000_106.7.674.26","doi-asserted-by":"publisher","DOI":"10.1186\/1546-0096-7-18"},{"key":"2022100607501402000_106.7.674.27","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1111\/apa.14417","article-title":"Easy-To-Use algorithm would provide faster diagnoses for mucopolysaccharidosis type I and enable patients to receive earlier treatment","volume":"107","author":"Tylki-Szyma\u0144ska","year":"2018","journal-title":"Acta Paediatr"},{"key":"2022100607501402000_106.7.674.28","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s00431-019-03330-x","article-title":"Growth impairment and limited range of joint motion in children should raise suspicion of an attenuated form of mucopolysaccharidosis: expert opinion","volume":"178","author":"Guffon","year":"2019","journal-title":"Eur J Pediatr"},{"key":"2022100607501402000_106.7.674.29","doi-asserted-by":"crossref","DOI":"10.1186\/s12902-018-0311-x","article-title":"Short stature as a presenting symptom of attenuated Mucopolysaccharidosis type I: case report and clinical insights","volume":"18","author":"Martins","year":"2018","journal-title":"BMC Endocr Disord"},{"key":"2022100607501402000_106.7.674.30","doi-asserted-by":"crossref","first-page":"172","DOI":"10.3390\/diagnostics10030172","article-title":"Diagnosis of Mucopolysaccharidoses","volume":"10","author":"Kubaski","year":"2020","journal-title":"Diagnostics"},{"key":"2022100607501402000_106.7.674.31","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.jpeds.2016.11.036","article-title":"Mucopolysaccharidosis Type I newborn screening: best practices for diagnosis and management","volume":"182","author":"Clarke","year":"2017","journal-title":"J Pediatr"},{"key":"2022100607501402000_106.7.674.32","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.ymgme.2016.12.010","article-title":"Glycosaminoglycan levels in dried blood spots of patients with mucopolysaccharidoses and mucolipidoses","volume":"120","author":"Kubaski","year":"2017","journal-title":"Mol Genet Metab"},{"key":"2022100607501402000_106.7.674.33","doi-asserted-by":"crossref","DOI":"10.1186\/1750-1172-8-147","article-title":"A pilot newborn screening program for Mucopolysaccharidosis type I in Taiwan","volume":"8","author":"Lin","year":"2013","journal-title":"Orphanet J Rare Dis"},{"key":"2022100607501402000_106.7.674.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2014.09.023"},{"key":"2022100607501402000_106.7.674.35","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1111\/apa.14587","article-title":"International working group identifies need for newborn screening for mucopolysaccharidosis type I but states that existing hurdles must be overcome","volume":"107","author":"Parini","year":"2018","journal-title":"Acta Paediatr"},{"key":"2022100607501402000_106.7.674.36","doi-asserted-by":"crossref","DOI":"10.1186\/s13052-018-0552-3","article-title":"Newborn screening in mucopolysaccharidoses","volume":"44","author":"Donati","year":"2018","journal-title":"Ital J Pediatr"},{"key":"2022100607501402000_106.7.674.37","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jpeds.2019.04.027","article-title":"The North Carolina experience with Mucopolysaccharidosis Type I newborn screening","volume":"211","author":"Taylor","year":"2019","journal-title":"J Pediatr"},{"key":"2022100607501402000_106.7.674.38","doi-asserted-by":"crossref","DOI":"10.1515\/cclm-2020-0064","article-title":"The combined use of enzyme activity and metabolite assays as a strategy for newborn screening of mucopolysaccharidosis type I","author":"Polo","year":"2020","journal-title":"Clin Chem Lab Med"},{"key":"2022100607501402000_106.7.674.39","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/cge.13583","article-title":"Genotype-Phenotype relationships in mucopolysaccharidosis type I (MPS I): insights from the International MPS I registry","volume":"96","author":"Clarke","year":"2019","journal-title":"Clin Genet"},{"key":"2022100607501402000_106.7.674.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.02.011"},{"key":"2022100607501402000_106.7.674.41","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-017-0662-9","article-title":"Open issues in Mucopolysaccharidosis type I-Hurler","volume":"12","author":"Parini","year":"2017","journal-title":"Orphanet J Rare Dis"},{"key":"2022100607501402000_106.7.674.42","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/gim.2018.29","article-title":"Long-Term outcomes of systemic therapies for Hurler syndrome: an international multicenter comparison","volume":"20","author":"Eisengart","year":"2018","journal-title":"Genet Med"}],"container-title":["Archives of Disease in Childhood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/archdischild-2020-319040","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T15:19:24Z","timestamp":1665069564000},"score":1,"resource":{"primary":{"URL":"https:\/\/adc.bmj.com\/lookup\/doi\/10.1136\/archdischild-2020-319040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,2]]},"references-count":42,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,6,18]]},"published-print":{"date-parts":[[2021,7]]}},"alternative-id":["10.1136\/archdischild-2020-319040"],"URL":"https:\/\/doi.org\/10.1136\/archdischild-2020-319040","relation":{},"ISSN":["0003-9888","1468-2044"],"issn-type":[{"value":"0003-9888","type":"print"},{"value":"1468-2044","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,2]]}}}